能倍乐气雾剂价格

It is developed by Boehringer Ingelheim and has a specification of 60 puffs/bottle + 1 Respirnt inhalation device/box. The spray is for inhalation only, and the recommended dose for adults is to inhale 2 puffs once a day at the same time through the Resplmat inhalation device. Respimat is mainly used to treat chronic obstructive pulmonary disease (COPD) in adults, and the price per box is around $170.

Respimat is a long-acting anticholinergic drug that selectively inhibits M3 receptors. It has the advantages of long maintenance of blood concentration and minimal side effects. It should be noted that Respimat is contraindicated in patients with allergic reactions to tiotropium bromide, atropine or their derivatives, such as ipratropium bromide or oxotropium bromide or the excipient lactose of this product.

In human airways, Respimat has a high affinity for receptors and dissociates slowly from muscarinic M1 and M3 receptors, and can block cholinergic nerve-mediated contraction of bronchial smooth muscle for a long time. However, Respimat dissociates from the muscarinic M2 receptor quite quickly, thus showing unique kinetic selectivity for M1 and M3 receptors.

Avoid spraying Respimat in the eyes and avoid overdosing during treatment. The most common adverse reactions of Respimat are dry mouth and cough, with an incidence rate of no more than 15%, followed by pharyngitis, upper respiratory tract infection, bitter mouth, transient allergic reactions, headache, nervousness, excitement, and dizziness. Rare systemic adverse reactions include urinary retention, prostatitis, constipation, tachycardia, and palpitations. Usually the side effects of Respimat are relatively mild. If patients experience serious adverse reactions during treatment, they need to contact their doctor in time.

The price is relatively low, the effect is good and the safety is high. If you need to purchase this medicine, you can consult the medical companion travel service for specific purchase information.

Recommended related hot articles: /newsDetail/82341.html